Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are ...

Minghui Pharmaceutical ( Minghui ), a late-stage clinical biopharmaceutical company, announced the closing of a $131 million ...